Document Detail

Effects of a competitive inhibitor (mevinolin) of 3-hydroxy-3-methylglutaryl coenzyme A reductase on human and bovine endothelial cells, fibroblasts and smooth muscle cells in vitro.
MedLine Citation:
PMID:  2666977     Owner:  NLM     Status:  MEDLINE    
Mevinolin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase activity, is a potent inhibitor of cholesterol synthesis. We have tested the effects of mevinolin on cell replication (3H-thymidine incorporation), prostacyclin production (6-keto-PGF1 alpha) and cell death (51Cr release) in cell cultures (human umbilical vein endothelial cells, bovine endothelial cells, human fibroblasts and bovine smooth muscle cells). Mevinolin concentrations ranging from 0.05 mumol/l (reported therapeutic concentration) to 20 mumol/l were used. In human endothelial cells the replication was reduced by 11% at a concentration of 2.0 mumol/l (P less than 0.01). In fibroblasts and smooth muscle cells the reduction was significant already at 0.1 mumol/l (10%, P less than 0.01). The prostacyclin production was reduced in endothelial cells at 1.0 mumol/l (19%, P less than 0.01) and in smooth muscle cells at 2.0 mumol/l (15%, P less than 0.05). At 20 mumol/l both cell replication and prostacyclin production was markedly reduced by about 40% in all cell types. No effects on 51Cr release or trypan blue staining was seen at any concentration. It is concluded that mevinolin has an effect on DNA synthesis and prostacyclin production on the tested cell types in vitro. These effects were, however, observed only at concentrations higher than those recommended for therapeutical use.
P Falke; I Mattiasson; L Stavenow; B Hood
Related Documents :
17523877 - Vascularization and improved in vivo survival of vegf-secreting cells microencapsulated...
9638517 - Cytotoxicity of some oxysterols on human vascular smooth muscle cells was mediated by a...
19288517 - A high mobility group b-1 box a peptide combined with an artery wall binding peptide ta...
20965167 - Community effect triggers terminal differentiation of myogenic cells derived from muscl...
4372617 - Biological activity of a growth factor for ovarian cells.
15713547 - Cytotoxicity of metals common in mining effluent to rainbow trout cell lines and to the...
Publication Detail:
Type:  In Vitro; Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Pharmacology & toxicology     Volume:  64     ISSN:  0901-9928     ISO Abbreviation:  Pharmacol. Toxicol.     Publication Date:  1989 Feb 
Date Detail:
Created Date:  1989-09-05     Completed Date:  1989-09-05     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8702180     Medline TA:  Pharmacol Toxicol     Country:  DENMARK    
Other Details:
Languages:  eng     Pagination:  173-6     Citation Subset:  IM    
Department of Medicine, University of Lund, Malmö General Hospital, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Cell Division / drug effects
Cell Survival / drug effects
DNA / biosynthesis
Endothelium, Vascular / drug effects*,  metabolism
Epoprostenol / biosynthesis
Fibroblasts / drug effects*,  metabolism
Hydroxymethylglutaryl-CoA Reductase Inhibitors*
Lovastatin / pharmacology*
Muscle, Smooth, Vascular / drug effects*
Reg. No./Substance:
0/Hydroxymethylglutaryl-CoA Reductase Inhibitors; 35121-78-9/Epoprostenol; 75330-75-5/Lovastatin; 9007-49-2/DNA

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Characterization of complement activity in turkeys: evidence for classical and alternative complemen...
Next Document:  The role of free oxygen radicals in the expulsion of primary infections of Nippostrongylus brasilien...